The biological complexity of cancer represents a tremendous clinical challenge, resulting in
the frequent failure of current treatment protocols. In the rapidly evolving scenario of a …

Cancer cell dormancy is a common feature of human tumors and represents a major clinical
barrier to the long-term efficacy of anticancer therapies. Dormant cancer cells, either in …

Dormancy occurs when cells remain viable but stop proliferating. When most of a cancer
population undergoes this phenomenon, the result is called tumor dormancy, and when a …

Quiescence in cancer cells is considered a therapeutic challenge as it confers dormancy in
tumour, hence circumventing inherent anti-neoplastic surveillance system and standard-of …

The success of targeted therapies and immunotherapies has created optimism that cancers
may be curable. However, not all patients respond, drug resistance is common and many …

Disease relapse in cancer patients many years after clinical remission, often referred to as
cancer dormancy, is well documented but remains an incompletely understood …

Cancer cell dormancy is a process whereby cells enter reversible cell cycle arrest, termed
quiescence. Quiescence is essential for cancer cells to acquire additional mutations, to …

Background The ability of a tumor to become dormant in response to suboptimal conditions
has recently been recognized as a key step in tumor progression. Tumor dormancy has …

Cancer cell dormancy has emerged as an important nongenetic driver of drug resistance.
Dormant cells are characterized by a reversible cell cycle exit. They represent a reservoir for …

Over the years, developments in oncology led to significantly improved clinical outcome for
cancer patients. However, cancer recurrence after initial treatment response still poses a …